Terapia delle epatopatie colestiche croniche

Translated title of the contribution: Clinical management of chronic cholestatic liver diseases

M. Podda, P. Invernizzi, A. Crosignani

Research output: Contribution to journalArticle

Abstract

Management of chronic liver diseases requires treatment of both the underlying liver disease and multiple and often disabling symptoms associated with long-standing cholestasis, including pruritus, metabolic bone disease and malnutrition. Reliable data on the specific treatment are available only for primary biliary cirrhosis and therefore this review will mainly focus on such a disease. With the exception of supplemental therapy with fat soluble vitamins, treatment of the complications of longstanding cholestasis is often unsatisfactory, probably reflecting the poor comprehension of their pathogenesis. Several medical approaches have been proposed attempting to slow or halt progression of primary biliary cirrhosis. Randomized clinical trials have sanctioned penicillamine failure and the efficacy of ursodeoxycholic acid, whereas for several other agents, they have disclosed interesting perspectives, mainly in terms of treatment combinations. However, difficulties have been encountered in assessing long-term benefits of such agents due to the highly variable natural history of primary biliary cirrhosis. In conclusion, ursodeoxycholic acid was shown to delay but not to halt the progression of primary biliary cirrhosis and association therapies with immunosuppressive or antifibrotic agents have been suggested to improve efficacy.

Original languageItalian
Pages (from-to)131-138
Number of pages8
JournalOspedale Maggiore
Volume91
Issue number2
StatePublished - 1997
Externally publishedYes

Fingerprint

Biliary Liver Cirrhosis
Liver Diseases
Ursodeoxycholic Acid
Cholestasis
Penicillamine
Metabolic Bone Diseases
Pruritus
Immunosuppressive Agents
Vitamins
Malnutrition
Chronic Disease
Randomized Controlled Trials
Fats
Therapeutics

Keywords

  • Chronic cholestasis
  • Clinical management
  • Osteodystrophy
  • Primary biliary cirrhosis
  • Pruritus
  • Ursodeoxycholic acid

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Podda, M., Invernizzi, P., & Crosignani, A. (1997). Terapia delle epatopatie colestiche croniche. Ospedale Maggiore, 91(2), 131-138.

Terapia delle epatopatie colestiche croniche. / Podda, M.; Invernizzi, P.; Crosignani, A.

In: Ospedale Maggiore, Vol. 91, No. 2, 1997, p. 131-138.

Research output: Contribution to journalArticle

Podda, M, Invernizzi, P & Crosignani, A 1997, 'Terapia delle epatopatie colestiche croniche', Ospedale Maggiore, vol. 91, no. 2, pp. 131-138.
Podda M, Invernizzi P, Crosignani A. Terapia delle epatopatie colestiche croniche. Ospedale Maggiore. 1997;91(2):131-138.
Podda, M. ; Invernizzi, P. ; Crosignani, A. / Terapia delle epatopatie colestiche croniche. In: Ospedale Maggiore. 1997 ; Vol. 91, No. 2. pp. 131-138.
@article{10f713db5edd4b2687a4c72b90e7696e,
title = "Terapia delle epatopatie colestiche croniche",
abstract = "Management of chronic liver diseases requires treatment of both the underlying liver disease and multiple and often disabling symptoms associated with long-standing cholestasis, including pruritus, metabolic bone disease and malnutrition. Reliable data on the specific treatment are available only for primary biliary cirrhosis and therefore this review will mainly focus on such a disease. With the exception of supplemental therapy with fat soluble vitamins, treatment of the complications of longstanding cholestasis is often unsatisfactory, probably reflecting the poor comprehension of their pathogenesis. Several medical approaches have been proposed attempting to slow or halt progression of primary biliary cirrhosis. Randomized clinical trials have sanctioned penicillamine failure and the efficacy of ursodeoxycholic acid, whereas for several other agents, they have disclosed interesting perspectives, mainly in terms of treatment combinations. However, difficulties have been encountered in assessing long-term benefits of such agents due to the highly variable natural history of primary biliary cirrhosis. In conclusion, ursodeoxycholic acid was shown to delay but not to halt the progression of primary biliary cirrhosis and association therapies with immunosuppressive or antifibrotic agents have been suggested to improve efficacy.",
keywords = "Chronic cholestasis, Clinical management, Osteodystrophy, Primary biliary cirrhosis, Pruritus, Ursodeoxycholic acid",
author = "M. Podda and P. Invernizzi and A. Crosignani",
year = "1997",
language = "Italian",
volume = "91",
pages = "131--138",
journal = "Ospedale Maggiore",
issn = "0369-7843",
publisher = "Masson Italia Periodici",
number = "2",

}

TY - JOUR

T1 - Terapia delle epatopatie colestiche croniche

AU - Podda, M.

AU - Invernizzi, P.

AU - Crosignani, A.

PY - 1997

Y1 - 1997

N2 - Management of chronic liver diseases requires treatment of both the underlying liver disease and multiple and often disabling symptoms associated with long-standing cholestasis, including pruritus, metabolic bone disease and malnutrition. Reliable data on the specific treatment are available only for primary biliary cirrhosis and therefore this review will mainly focus on such a disease. With the exception of supplemental therapy with fat soluble vitamins, treatment of the complications of longstanding cholestasis is often unsatisfactory, probably reflecting the poor comprehension of their pathogenesis. Several medical approaches have been proposed attempting to slow or halt progression of primary biliary cirrhosis. Randomized clinical trials have sanctioned penicillamine failure and the efficacy of ursodeoxycholic acid, whereas for several other agents, they have disclosed interesting perspectives, mainly in terms of treatment combinations. However, difficulties have been encountered in assessing long-term benefits of such agents due to the highly variable natural history of primary biliary cirrhosis. In conclusion, ursodeoxycholic acid was shown to delay but not to halt the progression of primary biliary cirrhosis and association therapies with immunosuppressive or antifibrotic agents have been suggested to improve efficacy.

AB - Management of chronic liver diseases requires treatment of both the underlying liver disease and multiple and often disabling symptoms associated with long-standing cholestasis, including pruritus, metabolic bone disease and malnutrition. Reliable data on the specific treatment are available only for primary biliary cirrhosis and therefore this review will mainly focus on such a disease. With the exception of supplemental therapy with fat soluble vitamins, treatment of the complications of longstanding cholestasis is often unsatisfactory, probably reflecting the poor comprehension of their pathogenesis. Several medical approaches have been proposed attempting to slow or halt progression of primary biliary cirrhosis. Randomized clinical trials have sanctioned penicillamine failure and the efficacy of ursodeoxycholic acid, whereas for several other agents, they have disclosed interesting perspectives, mainly in terms of treatment combinations. However, difficulties have been encountered in assessing long-term benefits of such agents due to the highly variable natural history of primary biliary cirrhosis. In conclusion, ursodeoxycholic acid was shown to delay but not to halt the progression of primary biliary cirrhosis and association therapies with immunosuppressive or antifibrotic agents have been suggested to improve efficacy.

KW - Chronic cholestasis

KW - Clinical management

KW - Osteodystrophy

KW - Primary biliary cirrhosis

KW - Pruritus

KW - Ursodeoxycholic acid

UR - http://www.scopus.com/inward/record.url?scp=0030742857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030742857&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030742857

VL - 91

SP - 131

EP - 138

JO - Ospedale Maggiore

JF - Ospedale Maggiore

SN - 0369-7843

IS - 2

ER -